Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Income Statement [Abstract]
Net sales	$ 5,061	$ 4,120	$ 9,724	$ 7,977
Cost of products sold	1,637	1,270	3,090	2,479
Gross profit	3,424	2,850	6,633	5,498
Operating expenses:
Selling, general and administrative expenses	1,716	1,446	3,312	2,810
Research and development expenses	526	383	969	749
Royalty expense	14	9	28	19
Amortization expense	225	213	444	427
Intangible asset impairment charges	46	276	46	276
Contingent consideration net expense (benefit)	(5)	2	0	18
Restructuring net charges (credits)	83	1	93	5
Operating expenses	2,605	2,330	4,894	4,303
Operating income (loss)	819	520	1,740	1,195
Other income (expense):
Interest expense	(90)	(77)	(172)	(146)
Other, net	213	(23)	179	(21)
Income (loss) before income taxes	941	420	1,746	1,028
Income tax expense (benefit)	146	98	279	213
Net income (loss)	795	322	1,467	815
Net income (loss) attributable to noncontrolling interests	(2)	(2)	(4)	(4)
Net income (loss) attributable to Boston Scientific common stockholders	$ 797	$ 324	$ 1,471	$ 819
Net income (loss) per common share — basic	$ 0.54	$ 0.22	$ 0.99	$ 0.56
Net income (loss) per common share — diluted	$ 0.53	$ 0.22	$ 0.98	$ 0.55
Weighted-average shares outstanding
Basic	1,479.9	1,470.6	1,478.5	1,469.5
Diluted	1,493.5	1,484.2	1,493.3	1,483.0